Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer

BACKGROUND: Better predictors of patients with stage II/III gastric cancer (GC) most likely to benefit from adjuvant chemotherapy are urgently needed. This study aimed to assess the ability of CDX2 and mucin markers to predict prognosis and fluorouracil‐based adjuvant chemotherapy benefits. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xianchun, Han, Weili, Chen, Ling, Li, Hongwei, Zhou, Fenli, Bai, Bin, Yan, Junya, Guo, Yong, Liu, Kun, Li, Wenjiao, Li, Renlong, Yuan, Qiangqiang, Zhang, Jiehao, Lu, Yuanyuan, Zhao, Xiaodi, Ji, Gang, Li, Mengbin, Zhao, Qingchuan, Wu, Kaichun, Li, Zengshan, Nie, Yongzhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523976/
https://www.ncbi.nlm.nih.gov/pubmed/37602699
http://dx.doi.org/10.1002/cam4.6379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523976/
https://www.ncbi.nlm.nih.gov/pubmed/37602699
http://dx.doi.org/10.1002/cam4.6379

Ejemplares similares